Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
302 stopped studies mapped to Invasive Carcinoma and descendants · 92% state a reason
Over the 302 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computed
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT05368506 | ZN-c3 for the Treatment of Metastatic Triple-Negative Breast Cancer and Advanced Ovarian… | Early Phase 1 | withdrawn | May 10, 2022 | OHSU Knight Cancer Institute | PI discretion | Other (stated, no rule matched) |
| NCT04085991 | Two TraCer PositROn EmiSSion Tomography ComBination for Efficacy EstimatiOn of Prostate…(CROSSBOW) | Phase 2 | terminated | Sep 11, 2019 | Sir Mortimer B. Davis - Jewish General Hospital | Drug no longer available | Other (stated, no rule matched) |
| NCT05221827 | Clinical Performance Evaluation of the C2i-Test | — | terminated | Feb 3, 2022 | C2i Genomics | Not in line with company's recently updated clinical development strategy | Sponsor / business decision |
| NCT05744115 | Ga-68-PSMA-11 in Men With Prostate Cancer(Ga68-PSMA-11) | Phase 3 | terminated | Feb 24, 2023 | Timothy Hoffman | The investigational product was approved by the FDA (12/20/2021) and is now commercially available | Other (stated, no rule matched) |
| NCT02721979 | Apalutamide in Treating Patients With Prostate Cancer Who Are in Active Surveillance | Phase 2 | terminated | Mar 29, 2016 | University of Washington | Terminated due to slow accrual | Enrollment / accrual |
| NCT03982173 | Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and…(MATILDA) | Phase 2 | withdrawn | Jun 11, 2019 | Gustave Roussy, Cancer Campus, Grand Paris | Similar clinical trials showed not very encouraging results, which made us decide, after several… | Other (stated, no rule matched) |
| NCT02658812 | Talimogene Laherparepvec in Treating Patients With Recurrent Breast Cancer That Cannot Be… | Phase 2 | terminated | Jan 20, 2016 | M.D. Anderson Cancer Center | Per PI | Other (stated, no rule matched) |
| NCT03933813 | Evaluation and Treatment of Iron Deficiency in Ovarian Cancer Patients | Phase 1 / Phase 2 | terminated | May 1, 2019 | University of Wisconsin, Madison | slow accrual | Enrollment / accrual |
| NCT02454517 | Diet and Exercise Program to Promote Weight Loss and Improve Health in Men With Low- or…(PALS) | N/A | terminated | May 27, 2015 | Fred Hutchinson Cancer Center | Terminated due to insufficient funding | Funding |
| NCT04851834 | NTX-301 Monotherapy in Advanced Solid Tumours and in Combination With Platinum-based… | Phase 1 / Phase 2 | terminated | Apr 20, 2021 | Xennials Therapeutics Australia Pty Ltd | Study was terminated by IP Holder (collaborator), PinotBio Inc. | Other (stated, no rule matched) |
| NCT02978222 | Folate Receptor Alpha Peptide Vaccine With GM-CSF Versus GM-CSF Alone in Patients With… | Phase 2 | terminated | Nov 30, 2016 | Marker Therapeutics, Inc. | Futility analysis did not support continuation of the trial | Efficacy / futility |
| NCT05062174 | Breast Cancer BRCA1 Carriers: a Pilot Study | — | withdrawn | Sep 30, 2021 | Indiana University | PI decision to cancel research | Other (stated, no rule matched) |
| NCT05093387 | SGT-53, Carboplatin, and Pembrolizumab for the Treatment of Metastatic Triple Negative… | Phase 1 | withdrawn | Oct 26, 2021 | Northwestern University | funding issues and pharmacy preparation for the drug | Funding |
| NCT01174199 | Temsirolimus and Vorinostat in Treating Patients With Metastatic Prostate Cancer | Phase 1 | terminated | Aug 3, 2010 | Roswell Park Cancer Institute | no value in finding efficacy | Efficacy / futility |
| NCT03128619 | Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor… | Phase 1 | terminated | Apr 25, 2017 | Jonsson Comprehensive Cancer Center | Insufficient accrual | Enrollment / accrual |
| NCT05395260 | FL- 101 Study in Non-Metastatic MIBC | Early Phase 1 | withdrawn | May 27, 2022 | Flame Biosciences | Sponsor Decision | Sponsor / business decision |
| NCT04562298 | A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-M23,… | Phase 1 | terminated | Sep 24, 2020 | Shanghai East Hospital | Both the sponsors and collaborator are considering terminating the study. | Other (stated, no rule matched) |
| NCT04349111 | An Efficacy Study of the Xoft® Axxent® eBx® IORT System® "Lite" | N/A | withdrawn | Apr 16, 2020 | Xoft, Inc. | Lack of site participation | Other (stated, no rule matched) |
| NCT03382574 | Pilot Study of Denosumab in BRCA1/2 Mutation Carriers Scheduled for Risk-Reducing… | Early Phase 1 | terminated | Dec 26, 2017 | National Cancer Institute (NCI) | it was decided that due to lack of accrual on the trial, and low potential for accruing over the… | Enrollment / accrual |
| NCT03100006 | Phase Ib/IIa Trial to Evaluate Oregovomab and Nivolumab in Epithelial Cancer of Ovarian,…(ORION-01) | Phase 1 / Phase 2 | terminated | Apr 4, 2017 | National Cancer Centre, Singapore | The study had poor efficacy. | Efficacy / futility |
| NCT02900560 | Study of Pembrolizumab With or Without CC-486 in Patients With Platinum-resistant Ovarian… | Phase 2 | terminated | Sep 14, 2016 | Translational Research in Oncology | not stated | Not stated |
| NCT03839472 | Continuous Bladder Irrigation Following Transurethral Resection of Bladder Tumors | N/A | withdrawn | Feb 15, 2019 | Case Comprehensive Cancer Center | Revision to improve cell recovery | Other (stated, no rule matched) |
| NCT04331717 | Bariatric Arterial Embolization for Men Starting Hormones for Prostate Cancer(BASH-PC) | Phase 2 | withdrawn | Apr 2, 2020 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | accrual on hold | Enrollment / accrual |
| NCT03630653 | Sentinel Lymph Node Procedure in Ipsilateral Invasive Breast Cancer Relapse(FIGARO) | N/A | terminated | Aug 15, 2018 | Institut Cancerologie de l'Ouest | The study was stopped prematurely due to insufficient recruitment | Enrollment / accrual |
| NCT04795596 | Secondary Cytoreductive Surgery in Platinum-resistant Recurrent Ovarian Cancers | Phase 2 / Phase 3 | withdrawn | Mar 12, 2021 | Menoufia University | Poor accrual | Enrollment / accrual |
| NCT03924245 | Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant… | Phase 1 | terminated | Apr 23, 2019 | Vanderbilt-Ingram Cancer Center | Change in participant landscape and other treatment availability | Other (stated, no rule matched) |
| NCT04221828 | Trial of NanoPac Focal Therapy for Prostate Cancer | Phase 2 | terminated | Jan 9, 2020 | NanOlogy, LLC | Lack of enrollment | Enrollment / accrual |
| NCT04611139 | Pilot Trial of SP-2577 Plus Pembrolizumab in Select Gynecologic Cancers | Phase 1 | withdrawn | Nov 2, 2020 | HonorHealth Research Institute | Salarius discontinued support | Other (stated, no rule matched) |
| NCT03690739 | Evaluation of Symptom Benefit Rate of Trabectedin/PLD in Patients With Recurrent Ovarian… | Phase 3 | terminated | Oct 1, 2018 | AGO Research GmbH | Insufficient Recruitment | Enrollment / accrual |
| NCT01018563 | An Open Label Extension Study of the Efficacy of MORAb-003 | Phase 2 | terminated | Nov 23, 2009 | Morphotek | Study was terminated by sponsor due to futile results in NCT00849667 study. | Other (stated, no rule matched) |
| NCT02767921 | sEphB4-HSA Before Surgery in Treating Patients With Bladder Cancer, Prostate Cancer, or… | Phase 1 | terminated | May 11, 2016 | University of Southern California | Insufficient accrual | Enrollment / accrual |
| NCT02137252 | Naltrexone RCT for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for… | Phase 2 | terminated | May 13, 2014 | Dana-Farber Cancer Institute | no enough patients | Other (stated, no rule matched) |
| NCT03184558 | Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With TNBC | Phase 2 | terminated | Jun 12, 2017 | BerGenBio ASA | Based on planned futility assessment | Efficacy / futility |
| NCT01934335 | Effect of Vandetanib on Cellular Markers in Invasive Breast Cancer | Phase 2 | terminated | Sep 4, 2013 | Ronald Weigel | Drugs unavailable | Other (stated, no rule matched) |
| NCT03607955 | Paclitaxel + Carboplatin With AVB-S6-500 in Women With Stage III or IV Epithelial… | Phase 1 | withdrawn | Jul 31, 2018 | Washington University School of Medicine | Trial may move forward as an NCI-sponsored trial and not an investigator initiated trial. | Investigator |
| NCT04020094 | Perioperative Atezolizumab With MVA-BN-Brachyury and PROSTVAC For Intermediate-Risk And…(AtezoVax) | Phase 2 | withdrawn | Jul 15, 2019 | University of Utah | funding source withdrawn | Funding |
| NCT03608618 | Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian… | Phase 1 | terminated | Aug 1, 2018 | MaxCyte, Inc. | Sponsor shift in focus | Other (stated, no rule matched) |
| NCT03829930 | Combination of Entinostat and Enzalutamide in Advanced Prostate Cancer | Phase 1 | terminated | Feb 4, 2019 | George Washington University | Sponsor discontinued the drug | Other (stated, no rule matched) |
| NCT01755130 | Laser Optoacoustic and Ultrasonic Imaging System Assembly in Finding Changes in Tumors in… | N/A | terminated | Dec 24, 2012 | M.D. Anderson Cancer Center | due to lack of funding | Funding |
| NCT04498520 | Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic… | Phase 1 | withdrawn | Aug 4, 2020 | Pamela Munster | Funding | Funding |
| NCT03029585 | Phase II Study of Intraperitoneal NanoPac® in Patients With Ovarian Cancer | Phase 2 | terminated | Jan 24, 2017 | NanOlogy, LLC | Business reasons | Sponsor / business decision |
| NCT02853097 | Cell-Free DNA and RNA in Blood fromMetastatic Prostate Cancer Patients | — | terminated | Aug 2, 2016 | University of Southern California | Slow accrual | Enrollment / accrual |
| NCT03437915 | BrUOG 351: PRE-OPERATIVE APBI USING NIBB(351) | N/A | withdrawn | Feb 19, 2018 | Jaroslaw Hepel | Secondary to medicare coverage determination | Other (stated, no rule matched) |
| NCT01334047 | Trial of Vaccine Therapy in Recurrent Platinum Sensitive Ovarian Cancer Patients | Phase 1 / Phase 2 | terminated | Apr 12, 2011 | Steinar Aamdal | The study needed to be terminated due to new knowledge about cancer vaccines. A new protocol with… | Other (stated, no rule matched) |
| NCT02844582 | Cabazitaxel and Prednisone in Treating Patients With Metastatic Hormone-Resistant… | Phase 2 | terminated | Jul 26, 2016 | University of California, Davis | Poor accrual of subjects onto study | Enrollment / accrual |
| NCT03327662 | Utilising CTC Counts to Optimize Systemic Therapy of Metastatic Prostate Cancer(CTC-STOP) | Phase 3 | terminated | Oct 31, 2017 | Institute of Cancer Research, United Kingdom | Underrecruitment | Other (stated, no rule matched) |
| NCT04549584 | Neoadjuvant Chemotherapy Response in Metaplastic Carcinoma of Triple Negative Breast…(NEO-SMART) | — | terminated | Sep 16, 2020 | Seoul National University Hospital | due to poor enrolled patients | Enrollment / accrual |
| NCT02947152 | HKT288 in Solid Tumors, Including Epithelial Ovarian Cancer and Renal Cell Carcinoma | Phase 1 | terminated | Oct 27, 2016 | Novartis Pharmaceuticals | not stated | Not stated |
| NCT04399824 | Focal Radiation Therapy for the Treatment of Low or Intermediate-Risk Prostate Cancer | N/A | withdrawn | May 22, 2020 | Jonsson Comprehensive Cancer Center | Study did not open | Other (stated, no rule matched) |
| NCT03570476 | Olaparib Before Surgery in Treating Participants With Localized Prostate Cancer | Phase 2 | terminated | Jun 27, 2018 | University of Washington | Terminated due to slow accrual | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated May 6, 2023source: clinicaltrials